Publications

• Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

  N. Harbeck, A. Schneeweiss, P. Thuss-Patience, K. Miller, C. Garbe, F. Griesinger, W. E. E. Eberhardt, J. P. Klussmann, B. Wollenberg, M. O. Grimm, T. Zander, D. Lüftner

  PMID: 33611103 Show Details link to full text
  Study

  AMNOG

  Year

  2021

  Keywords

  • immunotherapy
  • oncology

• Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study i

  N. Teich, M. Bläker, F. Holtkamp-Endemann, E. Jörgensen, A. Stallmach, S. Hohenberger

  PMID: 33850839 Show Details link to full text
  Study

  MC Productive

  Year

  2021

  Keywords

  • Crohn's disease
  • infliximab
  • QoL
  • WPAI
  • HRQoL

• Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

  N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger

  PMID: 33845784 Show Details link to full text
  Study

  Go CUTE II

  Year

  2021

  Keywords

  • golimumab
  • ulcerative colitis
  • QoL
  • WPAI
  • HCRU

• Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

  V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck, T. Fehm, DETECT study group

  PMID: 34839105 Show Details link to full text
  Study

  DETECT

  Year

  2021

  Keywords

  • breast cancer
  • liquid biopsy
  • HER2
  • oncology

• A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer

  M. Hecht, D. Hahn, P. Wolber, M. G. Hautmann, D. Reichert, S. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, C. Große-Thie, O. Guntinas-Lichius, J. von der Grün, P. Balermpas, K. Orlowski, D. Messinger, K. G. Stenzel, R. Fietkau

  PMID: 34298628 Show Details link to full text
  Study

  SOCCER

  Year

  2021

  Keywords

  • cetuximab
  • head and neck cancer
  • oncology

• Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial

  L. Zimmer, A. Krackhardt, E. S. Schultz, D. Goeppner, C. Assaf, D. Trebing, E. Livingstone, D. Schadendorf

  PMID: Show Details link to full text
  Study

  IMMU-Target

  Year

  2021

  Keywords

  • pembrolizumab
  • encorafenib
  • binimetinib
  • oncology
  • BRAF mutation

• Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

  J. Roeper, S. Kurz, C. Grohé, F. Griesinger

  PMID: 33094641 Show Details link to full text
  Study

  Year

  2021

  Keywords

  • EGFR
  • NSCLC
  • tyrosine kinase inhibitor
  • oncology

• Klinisches Managment von PARP-Inhibitoren

  B. Schmalfeldt

  PMID: Show Details link to full text
  Study

  Year

  2021

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology

• Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

  L. Zimmer, E. Livingstone, J. C. Hassel, M. Fluck, T. Eigentler, C. Loquai, S. Haferkamp, R. Gutzmer, F. Meier, P. Mohr, A. Hauschild, B. Schilling, C. Menzer, F. Kieker, E. Dippel, A. Rösch, J. C. Simon, B. Conrad, S. Körner, C. Windemuth-Kieselbach, L. Schwarz, C. Garbe, J. C. Becker, D. Schadendorf; Dermatologic Cooperative Oncology Group

  PMID: 32416781 Show Details link to full text
  Study

  IMMUNED

  Year

  2020

  Keywords

  • melanoma
  • ipilimumab
  • nivolumab
  • oncology

• Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration

  A. Ebneter, S. Michels, C. Pruente, P. Imesch, F. Eilenberger, S. Oesch, I. P. Thomet-Hunziker, K. Hatz

  PMID: 33219242 Show Details link to full text
  Study

  Asteria

  Year

  2020

  Keywords

  • nAMD
  • aflibercept